Florida’s Institute for the Commercialization of Public Research has finalized a funding agreement with Heart Genomics, LLC, a Miami-based early-stage biotechnology company focused on providing non-invasive, genomic-based, clinical diagnostic tests for patients with heart failure. The ICPR works with Florida’s research universities and institutions to support new company creation and job growth, and the program bridges funding gaps, enabling recipients to reach critical milestones and attract additional private investment capital.
Heart Genomics is at the forefront of the burgeoning molecular diagnostics market. The new diagnostic tests will provide personalized and individualized information to each patient and their physician through the genomic analysis of the patient’s heart tissue or blood sample, and with this information, the heart patient and physician can make substantially improved and clear treatment decisions.
“This initial round of funding matched by the Institute for the Commercialization of Public Research will allow us to bring brand new diagnostic tools to doctors treating patients with congestive heart failure. The Heart Genomics tests will allow doctors to improve dramatically their ability to establish cause for heart failure and to allocate advanced therapies,” said Joshua Hare, M.D., Scientific Founder of Heart Genomics.
“Heart Genomics, with its genomics-based cardiovascular diagnostics, exemplifies the great work being done right here in Florida,” said Jamie Grooms, Institute Chief Executive Officer. The company’s tests, which are based on technology developed at the University of Miami’s Interdisciplinary Stem Cell Institute, headed by Dr. Hare, have a potential of bringing great advancements in the field of personalized medicine.